Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study

Izanne Roos; Sifat Sharmin; Serkan Ozakbas; Raed Alroughani; Sara Eichau; François Grand’Maison; Cavit Boz; Jeannette Lechner-Scott; Katherine Buzzard; Alexandre Prat; Samia J. Khoury; Pierre Grammond; Anneke van der Walt; Yolanda Blanco; Matteo Foschi; Aysun Soysal; Michael Barnett; Julie Prevost; Murat Terzi; Oliver Gerlach; Richard Macdonell; Maria Jose Sa; Daniele Spitaleri; Guy Laureys; Vincent van Pesch; Nevin John; Elisabetta Cartechini; Riadh Gouider; Davide Maimone; Cristina Ramo-Tello; Suzanne Hodgkinson; Mark Slee; Pamela McCombe; Justin Garber; Jose Luis Sanchez-Menoyo; Abdullah Al-Asmi; Allan G. Kermode; Emmanuelle Lapointe; Vahid Shaygannejad; Bart Van Wijmeersch; Barbara Willekens; Tamara Castillo-Triviño; Bruce Taylor; Guillaume Mathey; Emmanuelle Le Page; Jerome De Seze; Aurelie Ruet; Pierre Clavelou; Eric Berger; Helene Zephir; Arnaud Kwiatkowski; Jean Pelletier; Thibault Moreau; Pierre Labauge; Jonathan Ciron; Christine Lebrun-Frenay; Caroline Papeix; Gilles Defer; David Axel Laplaud; Eric Thouvenot; Bruno Stankoff; Elisabeth Maillart; Abdullatif Al-Khedr; Bertrand Bourre; Olivier Casez; Amélie Dos Santos; Jean-Philippe Camdessanche; Karolina Hankiewicz; Abir E. Abdel Wahab; Philippe Cabre; Olivier Heinzlef; Corinne Pottier; Solène Moulin; Laurent Magy; Céline Labeyrie; Inès Doghri; Sandra Vukusic; Tomas Kalincik; the MSBase and OFSEP Study Groups

doi:10.1007/s40263-026-01287-8

April 4, 2026CNS DrugsOpen Access

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the impact of high-efficacy disease-modifying therapies (HE-DMTs) on neurological function in individuals at varying risk of aggressive multiple sclerosis (MS).
Conducted an observational cohort study
Compared outcomes between HE-DMT-treated and untreated groups
Evaluated relapse rates and disability outcomes among patients using HE-DMT
HE-DMTs reduced relapse rates in both high and low risk MS patients
No significant difference in long-term disability outcomes between treated and untreated individuals
Disability worsening was less frequent in patients treated with HE-DMT

Implication

Observational cohort study shows HE-DMTs reduce relapse risk in aggressive multiple sclerosis, indicating potential benefits for all patients.

Abstract

HE-DMTs reduced the risk of relapse in people at both high and low risk of aggressive MS, with no evidence of differential treatment benefit. In the overall population, no evidence of a difference in disability outcomes between HE-DMT-treated and HE-DMT-untreated time was observed. However, among patients ever exposed to HE-DMT, disability worsening was less common while treated with HE-DMT.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Roos et al. (2026) studied this question.

synapsesocial.com/papers/69d49ecbb33cc4c35a227833 https://doi.org/10.1007/s40263-026-01287-8

View Full Paper

Ask AI

Bookmark

Share

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study

Key Points

Implication

Abstract

Discussion

Cite This Study

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading